Most Read Articles
27 Nov 2017
The amino sulphonic acid taurine may safely and effectively reduce portal pressure in cirrhotic patients, a study has shown.
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Rachel Soon, 3 days ago

Pharmaceutical industry representatives highlighted lesser-known career opportunities for licensed pharmacists at the recent Pharmaceutical Industries Pharmacists Insights 3.0 (PIPI 3.0) symposium in Petaling Jaya.

Lithium exposure during pregnancy ups risk of congenital, cardiac anomalies

25 Oct 2019
Expecting mothers who takes painkillers during their pregnancy may risk having children with ADHD, study shows.

Lithium exposure at any time during pregnancy among women with bipolar disorder is associated with certain dangers, and such risk is greater for first-trimester or higher-dosage exposure, reveals a study.

This systematic review and meta-analysis evaluated case-control, cohort and interventional studies reporting on the safety (primary outcome: any congenital anomaly) or efficacy (primary outcome: mood relapse prevention) of lithium treatment during pregnancy and the postpartum period. The investigators used the Newcastle-Ottawa Scale and the Cochrane risk of bias tools to assess the quality of available PubMed and Scopus records through October 2018.

Twenty-nine studies met the inclusion criteria, of which 20 were of good quality and six of poor quality; one study had an unclear risk of bias and two had a high risk of bias. Thirteen studies could be included in the quantitative analysis.

Lithium prescribed during pregnancy led to an increased risk of any congenital anomaly (n=23,300, k=11; prevalence=4.1 percent, k=11; odds ratio [OR], 1.81, 95 percent CI, 1.35–2.41; number needed to harm [NNH], 33, 22–77) and of cardiac anomalies (n=1,348,475, k=12; prevalence=1.2 percent, k=9; OR, 1.86, 1.16–2.96; NNH, 71, 48–167). Moreover, first-trimester exposure to lithium correlated with greater odds of spontaneous abortion (n=1,289, k=3; prevalence=8.1 percent; OR, 3.7, 1.15–12.39; NNH, 15, 8–111).

Significance persisted when comparing lithium-exposed and unexposed pregnancies for any malformation (exposure during any pregnancy period or first trimester) and cardiac malformations (exposure during first trimester), but not for spontaneous abortion (exposure during first trimester) and cardiac malformations (exposure during any pregnancy period).

Treatment with lithium was better than no treatment at preventing postpartum relapse (n=48, k=2; OR, 0.16, 0.03–0.89; number needed to treat, 3, 1–12). Furthermore, mothers with serum lithium levels <0.64 mEq/L and dosages <600 mg/day had more reactive newborns without an increased risk of cardiac malformations, as shown in qualitative synthesis.

“Ideally, pregnancy should be planned during remission from bipolar disorder and lithium prescribed within the lowest therapeutic range throughout pregnancy, particularly during the first trimester and the days immediately preceding delivery, balancing the safety and efficacy profile for the individual patient,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
27 Nov 2017
The amino sulphonic acid taurine may safely and effectively reduce portal pressure in cirrhotic patients, a study has shown.
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Rachel Soon, 3 days ago

Pharmaceutical industry representatives highlighted lesser-known career opportunities for licensed pharmacists at the recent Pharmaceutical Industries Pharmacists Insights 3.0 (PIPI 3.0) symposium in Petaling Jaya.